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Abstract
We re-annotated the interacting partners of the neuronal scaffold protein DISC1 using a knowledge-based approach that
incorporated recent protein interaction data and published literature to. This revealed two highly connected networks.
These networks feature cellular function and maintenance, and cell signaling. Of potentially greatest interest was the
novel finding of a high degree of connectivity between the DISC1 scaffold protein, linked to psychiatric illness, and
huntingtin, the protein which is mutated in Huntington’s disease. The potential link between DISC1, huntingtin and their
interacting partners may open new areas of research into the effects of pathway dysregulation in severe neurological
disorders.
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Introduction
Disrupted in Schizophrenia, DISC1, is one of the most
convincing candidate genes for schizophrenia and related major
mental illness [1]. DISC1 is a scaffold protein that interacts with
multiple neurodevelomental, cytoskeletal and signaling proteins
[2], several of which have been independently associated with
major psychiatric illness [1]. Here, we update a previous analysis
of the Disrupted in Schizophrenia, DISC1, interactome [2],
seeking emergent evidence for novel linkages to other pathogenic
pathways. The re-analysis of this dataset has revealed a strong
network linking DISC1 and huntingtin protein, which is mutated
in Huntington’s disease [3], consistent with DISC1 and huntingtin
regulating convergent pathways. We hypothesise that mutation in
both DISC1 and HTT impact on a common pathway
underpinning major psychiatric illness. It will be important now
to test the effect of pathological mutation and genetic variation
with the normal range in DISC1, HTT and intermediate genes on
this convergent pathway.
In 2007, Carmargo et al. reported the results of a series of
yeast two-hybrid screens using DISC1 and key interactors:
CDC5L, CDK5RAP3, CEP63, DTNBP1, NDEL1, SEC3L1,
SH3BP5, TNIK, TRAF3IP1 [2]. Their network analysis
implicated DISC1 as a hub or scaffold protein with critical roles
in cytoskeletal stability and organisation, intracellular transport,
cell-cycle/division and synaptic function. Here, we revisit the
question of DISC1 function through network analysis and
identify multiple links to huntingtin (HTT), suggesting an
overlapping pathway of vulnerability between DISC1-related
psychiatric disorders and Huntington’s disease, a neurodegener-
ative disorder characterized by a deterioration in motor,
cognitive, and emotional function.
Results
The protein set originally identified by Camargo et al (see
Supplementary Information Table 3 within Camargo et al [2]) was
subjected to Ingenuity Pathway Analysis (IPA, Ingenuity Systems),
a knowledge-based functional annotation programme. Of the 150
genes in the raw gene list, 139 were mapped within the knowledge-
base and 133 were network eligible. Network sizes were limited to
a maximum of 140 molecules. Only direct interactions were
permitted, however data sources used included Additional
interactions, Ingenuity Expert Findings, MicroRNA-mRNA
interactions, or Protein-protein interactions. Two extensive and
highly connected, and thus high scoring, networks were identified:
Cellular Function and Maintenance, Cell Cycle, Cellular Assem-
bly and Organization, with an IPA score of 205 containing 96 key
molecules (Figure S1); and Cell Signaling, DNA Replication,
Recombination, and Repair, Nucleic Acid Metabolism, with an
IPA score of 79 containing 49 key molecules (Figure S2). Of the
molecules not in the original dataset that were added by the
program to create these networks, several, such as PDE4D and
FEZ1 are well documented DISC1 interactors [2], as well as
DISC1 itself, were identified successfully.
The highest scoring network, Cellular Function and Mainte-
nance, Cell Cycle, Cellular Assembly and Organization (Figure
S1), contained hub molecules (defined as those with greater than
10 connections) which included cytoskeletal components: tubulin,
actin, dynactin, the NDEL1/PAFAH1B1 (also known as LIS1)
complex, as well as 14-3-3 proteins (including YWHAZ), the
exocyst complex, CDC5L and TNIK. This network contained
very few proteins not on the original input list, and did not include
DISC1. Proteins added from the knowledge-base included:
REM1, CLIC5, and the NMDA receptor pathway, suggesting
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interactome. This may reflect the recent report that DISC1
regulates the activation of Rac1 in response to NMDA receptor
activation [4], which is also reflected in the addition of NMDA
receptors and RAC1 to the second network, and indicates
involvement of this complex as a direct link between the
interactors AKAP9 and SMC3.
In the second highest scoring network, Cell Signaling, DNA
Replication, Recombination, and Repair, Nucleic Acid Metabo-
lism (Figure S2), the updated knowledge-base introduced several
new molecules. These included PDE4D and FEZ1, which are
linked to DISC1 through both protein interaction and functional
experimental data [5–8]. Unsurprisingly, DISC1 formed a major
hub protein within this network with 44 connecting proteins. What
was striking, however, was the addition of the huntingtin protein
(HTT) as an extremely well connected hub protein with 57
connections. No direct connection was made between DISC1 and
HTT, but numerous proteins, both those on the input list and
those added from the current knowledge-base, provided single step
connections between these two neurologically important proteins.
Statistical analysis of the overlap in interacting proteins identified
in this IPA analysis gave a significant enrichment of DISC1
interactors within the proteins connected to HTT in Network 2
(P,0.001). To avoid any bias that may result from building this
interaction network from DISC1 interactors, we have further
analysed the lists of interactors of DISC1 and HTT from the EBI
IntAct database (www.ebi.ac.uk/intact/) and again found signif-
icant enrichment of DISC1 interactors in the list of HTT
interactors (P=0.007). Known DISC1 interactors linking DISC1
to HTT in the second network included: FEZ1, IMMT, DPYSL2
(also known as CRMP2), GPRASP2, GNB1 and PDE4B. These
are proteins with key functions in mitochondrial activity and
trafficking, axon outgrowth and neuronal signaling. KIAA1377
was added to this network from the knowledge-base. KIAA1377,
which interacts with FEZ1, IMMT, DISC1 and HTT, is localised
in the midbody and believed to play a critical role in cytokinesis
progression [9]. Other hub proteins in this network, and identified
from the knowledge-base include: the NMDA receptors (GRIN1
and GRIN2B), MAP3K3 and DTNBP1.
Discussion
Millar et al. [10] originally identified HAPIP, huntingtin-
associated protein – interacting protein (also known as Kalirin) as a
putative interactor of DISC1, a finding comfirmed by Camargo et
al [2] (Network 1), but no direct link to HTT was made. Our
updated analysis identifies multiple connections between the
DISC1 and HTT pathways and reflects the impact of recent
additions to the experimental knowledge base. In addition, three
further links involving interactions with intermediate proteins, and
not represented in the knowledge-base, have been established
between DISC1 and huntingtin. Firstly, the interaction of the
schizophrenia candidate gene PCM1 and HAP1, huntingtin-
associated protein 1, has been confirmed [11–13]. More directly,
both N-CoR and GRB2 have been confirmed as interaction
partners of both DISC1 and HTT [14–18].
The knowledge-based link between DISC1 and HTT highlights
possible common modes of action; and suggests that common
mechanisms influencing brain vulnerability may be shared
between schizophrenia /related psychiatric disorders of complex
genetic aetiology and the autosomal dominant disorder of
Huntington’s disease. Biological support for such a connection
comes from the cognitive deficits seen in both disorders, and
mouse models. Individuals with mutant huntingtin show deficits in
general intelligence tests, memory, and language tasks, even prior
to the onset of abnormal motor symptoms [19,20]. These are key
areas of vulnerability in schizophrenia and have been highlighted
in studies on psychiatric illness associated with DISC1 [1].
Strikingly, the cognitive deficits seen in a mouse model of
Huntington’s disease (R6/1) can be rescued by the antipsychotic
drug fluoxetine, a potent inhibitor of phosphodiesterase type IV
(PDE4A, B, C and D) [21]. Survival rates, hindlimb clasping (a
measure of neurological abnormality), and brain atrophy are also
significantly reduced by rolipram treatment in the R6/2 mouse
model of Huntington’s disease [22,23]. In the Disc1 mutant
mouse, L100P, which lies with a missense PDE4B-specific binding
site in exon 2, rolipram treatment improves the behavioural and
cognitive deficits seen in this model of schizophrenia [24].
Although, rolipram treatment had no effect on the depression-
like symptoms seen in the Disc1 Q31L mutant mouse [24].
Interestingly, the major diagnosis in the original t(1:11) DISC1
translocation family was that of recurrent major depression (10
individuals), as well as schizophrenia (7 individuals) [25]. Patients
diagnosed with Huntington’s disease show high rates depression,
although it is as yet unclear whether this is a co-morbidity or a
direct link [26–29]. Conversely, individuals with major depression
have been shown to have elevated rates of the huntingtin disease-
associated alleles (3 allele carriers in 1,000 patients, [30]).
However, psychotic schizophrenia-like symptoms have also been
noted amongst Huntington’s disease patients [31,32,33] consistent
with the interaction of huntingtin with proteins from other
schizophrenia-associated genes such as PCM1, PDE4B and
DPYSL2 [11–13,34–36]. It is therefore unclear whether the
overlap on the effects of disruption of DISC1 and HTT overlap
within the domains of depression or schizophrenia.
Indeed, Humbert (2010) has recently suggested that Hunting-
ton’s disease, like schizophrenia, may have a neurodevelopmental
aetiology, with HTT acting as a scaffold protein for many
developmental processes critical for correct brain function [36]. Of
those that she highlighted, many overlap with known DISC1
functions including: cortical neurogenesis, cell division, regulation
of the dynein-dynactin complex, and of b-catenin and the Wnt
signaling pathway (through regulation of the b-catenin destruction
complex). In addition, NMDA receptors appear in both the
DISC1 networks in this study suggesting a possible link through
NMDA receptor signaling. Huntingtin is a positive transcriptional
regulator of other NRSE-containing genes involved in the
maintenance of the neuronal phenotype (NRSE, neuron-restrictive
silencer element, [37,38]). Zuccato et al. reported that wild type
huntingtin acts on NRSE-containing genes include synaptophysin,
NMDA receptor subunits, GABA receptor subunits, acetylcholine
receptor alpha 7 and sodium channel genes [37]. Proteins involved
in mitochondrial function and/or localisation are identified in the
second network as intermediate steps between DISC1 and HTT
(i.e. IMMT, DCTN1, DCTN2). Mitochondrial dysfunction in
Huntington’s disease has recently gained attention [39–42]. In
Huntington’s disease, mutant huntingtin protein induces mito-
chondrial fragmentation and neuronal cell death [43,44]. Drp1
mediates mitochondrial fission and is a known GSK3B interacting
protein, DISC1 is known to alter GSK3B activity, and
overexpression of DISC1 results in a mitochondrial fission/fusion
phenotype [45]. It is therefore possible that disruptions of DISC1
or HTT resulting in cognitive deficits are the result of alterations
in mitochondrial function. The precise functional overlap between
the effects of these genes on liability to mental illness thus awaits
experimental validation.
One common limitation of this type of analysis is that the
absence of evidence is not evidence of absence. Thus, whereas
DISC1 and HTT
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interact directly, the number of confirmed interactors that they are
seen to have in common makes this a reasonable and testable
hypothesis. If demonstrated, this would be give further support for
our core hypothesis that the DISC1 and huntingtin pathways are
functionally linked. Either way, our updated network analysis
provides strong evidence for a link between DISC1 and HTT, and
thus implies a degree of biological commonality between the
neurological disorders of Huntington’s disease and of schizophre-
nia and related major psychiatric illness. Consideration of this
possibility may be instructive in relation to the psychopathological
components underlying differential DSM diagnoses and for
devising, testing and utilising therapeutic approaches developed
primarily for one or the other set of clinical manifestations.
Methods
The protein list was analysed in Ingenuity Pathway Analysis
using the core analysis allowing only direct interactions and with a
network size of 140 molecules (run date: 24/05/2010).
Tests for significant enrichment of DISC1 interacting proteins
within lists of HTT interacting proteins were performed using the
hypergeometric test implemented in Excel.
Supporting Information
Figure S1 DISC1 Interactome Network 1. Only direct
interactions were used. Molecules in the input list are in filled in
grey.
(JPG)
Figure S2 DISC1 Interactome Network 2. Only direct
interactions were used. Molecules in the input list are in filled in
grey.
(JPG)
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